News | November 10, 2023
GSK registers 5% revenue growth in Q2 FY24
General Medicine grows 5% and Vaccines 10% led by Shingrix
General Medicine grows 5% and Vaccines 10% led by Shingrix
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Profit After Tax (PAT) for the quarter ended December 31, 2022 was at Rs. 290.8 crore as compared to Rs. 239.8 crore in the previous corresponding quarter, registering a growth of 21.3% YoY
Profit after Tax stood at Rs. 106 crore as compared to Rs. 84 crore registering growth of 26%
International Business is expected to post double-digit revenue growth during the quarter in constant currency.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Glenmark Pharmaceuticals announced its financial results for the fourth quarter ended March 31, 2022
Ind-Ra maintains a neutral outlook for healthcare in FY23
Subscribe To Our Newsletter & Stay Updated
